Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis

Background: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are effective anti-diabetic drugs improving cardiovascular outcomes in type 2 diabetes mellitus (T2DM) patients. This study investigated cardiovascular, cerebrovascular and cognitive outcomes of SGLT2i therapy in patients with atrial fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Proietti, Riccardo, Rivera-Caravaca, José Miguel, López-Gálvez, Raquel, Harrison, Stephanie L., Marín, Francisco, Underhill, Paula, Shantsila, Eduard, McDowell, Garry, Vinciguerra, Manlio, Davies, Rhys, Giebel, Clarissa, Lane, Deirdre A., Lip, Gregory Y. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142574/
https://www.ncbi.nlm.nih.gov/pubmed/37109151
http://dx.doi.org/10.3390/jcm12082814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142574/
https://www.ncbi.nlm.nih.gov/pubmed/37109151
http://dx.doi.org/10.3390/jcm12082814

Ejemplares similares